坦度螺酮治疗伴有焦虑抑郁的功能性消化不良的疗效及对生存质量的影响

目的: 观察坦度螺酮治疗伴有焦虑抑郁的功能性消化不良（FD）的临床疗效及对生存质量的影响。方法: 将98例伴有焦虑抑郁的FD患者随机分为治疗组和对照组，每组49例。对照组给予泮托拉唑和莫沙必利口服，治疗组在此基础上加用坦度螺酮口服治疗，疗程4周。观察两组临床疗效及不良反应。结果: 治疗组在治疗后的FD症状、汉密顿抑郁量表（HAMD）及汉密顿焦虑量表（HAMA）评分均较治疗前显著下降（P<0.01），而功能性消化不良生存质量量表（FDDQL）评分则较治疗前明显升高，且与对照组比较差异有统计学意义（P<0.01）。治疗组的总有效率（85.7%）显著高于对照组（63.3%）(χ2=6.49，P<0.05)。两组未见明显不良反应。结论: 坦度螺酮治疗伴有焦虑抑郁的FD安全、有效，能显著改善患者的焦虑抑郁症状及生存质量。

Efficacy of tandospirone in treating functional dyspepsia accompanied by anxiety and depression and its influence on quality of life

AIM: To observe the clinical efficacy of tandospirone in the treatment of functional dyspepsia (FD) accompanied by anxiety and depression and its influence on quality of life. METHODS: Ninety-eight cases with FD accompanied by anxiety and depression were randomly divided into treatment group and control group (n=49). Patients of control group were treated with oral pantoprazole and mosapride. On the basis of control group, the treatment group was given oral tandospirone for four weeks. The therapeutic effect and adverse effects were observed and compared in both groups. RESULTS: Compared with before treatment, the scores of FD symptoms, Hamilton Rating Scale for Despression (HAMD) and Hamilton Anxiety Scale (HAMA) in treatment group decreaed significantly after treatment, while the score of Functional Digestive Disorders Quality of Life Questionnaire (FDDQL) increased significantly (all P<0.01); the decrease of FD symptoms,HAMD,HAMA scores and the increase of FDDQL scores of treatment group were greater than those of control group (all P<0.01). The total effective rate of treatment group was significantly higher than that of control group (87.5% vs. 63.3%, χ²=6.49, P<0.05). There was no obvious adverse effect recurred in both groups. CONCLUSION: Tandospirone is a safe and effective drug for FD accompanied by anxiety and depression; it can effectively improve the symptoms of anxiety, depression and quality of life of patients.